Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 13/20 | 0.51 |
| ▸ | ADK | P55263 | 2/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885861 | 1.00 | PRMT5 (0.51) | PRMT5WDR77ADKHASPIN | |
| SCHEMBL3882863 | 0.88 | PRMT5 (0.49) | PRMT5WDR77ADK | |
| SCHEMBL3882859 | 0.87 | PRMT5 (0.48) | PRMT5WDR77ADKHASPIN | |
| SCHEMBL3878325 | 0.86 | PRMT5 (0.53) | PRMT5WDR77ADK | |
| SCHEMBL5072407 | 0.84 | PRMT5 (0.52) | PRMT5WDR77ADK | |
| SCHEMBL6101377 | 0.84 | PRMT5 (0.52) | PRMT5WDR77ADK | |
| SCHEMBL5072399 | 0.84 | PRMT5 (0.52) | PRMT5WDR77ADK | |
| SCHEMBL5073145 | 0.82 | PRMT5 (0.49) | PRMT5WDR77ADK | |
| SCHEMBL27580357 | 0.79 | ADK (0.66) | PRMT5WDR77ADKHASPIN | |
| SCHEMBL2143266 | 0.78 | ADK (0.62) | ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2107909-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX Pharmaceuticals, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-7081449-B2 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | VALEANT RESEARCH & DEVELOPMENT (US) | 2006-07-25 | — | — | US | disclosed |
| US-20030144502-A1 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | MDRNA RESEARCH, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144502-A1 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | DPYD, TYMP, PNPO | PRMT5 2931/4885WDR77 2222/4885ADK 384/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | PRMT5 673/4885WDR77 820/4885ADK 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.